Results: The cohort included 54 hormone receptor (HR)-positive/HER2-negative (HR+/HER2−), 21 HR+/HER2+, 16 HR−/HER2+, and 14 triple-negative breast cancer (TNBC) patients. The gene discussed is HR; the disease is triple-negative breast carcinoma.